Nikko Asset Management Americas, Inc. Bristol Myers Squibb CO Transaction History

Nikko Asset Management Americas, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$59.17 - $69.31 $11.5 Million - $13.5 Million	-194,780 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$61.91 - $67.42 $4.56 Million - $4.97 Million	-73,723 Reduced 27.46%	194,780 $12.9 Million
Q1 2021 May 03, 2021	BUY	$59.34 - $66.74 $1.92 Million - $2.16 Million	32,292 Added 13.67%	268,503 $17 Million
Q4 2020 Feb 11, 2021	BUY	$57.74 - $65.43 $1.21 Million - $1.37 Million	20,985 Added 9.75%	236,211 $14.7 Million
Q3 2020 Nov 02, 2020	SELL	$57.43 - $63.64 $1.06 Million - $1.17 Million	-18,378 Reduced 7.87%	215,226 $12.9 Million
Q2 2020 Aug 07, 2020	SELL	$54.82 - $64.09 $9.84 Million - $11.5 Million	-179,430 Reduced 43.44%	233,604 $13.7 Million
Q1 2020 Apr 30, 2020	SELL	$46.4 - $67.43 $7.16 Million - $10.4 Million	-154,370 Reduced 27.21%	413,034 $23 Million
Q4 2019 Feb 06, 2020	SELL	$49.21 - $64.19 $15.6 Million - $20.4 Million	-317,653 Reduced 35.89%	567,404 $36.4 Million
Q3 2019 Oct 29, 2019	BUY	$42.77 - $50.71 $3.46 Million - $4.1 Million	80,818 Added 10.05%	885,057 $44.9 Million
Q2 2019 Jul 29, 2019	BUY	$44.62 - $49.34 $24.6 Million - $27.2 Million	551,258 Added 217.9%	804,239 $36.5 Million
Q1 2019 Apr 30, 2019	BUY	$45.12 - $53.8 $11.4 Million - $13.6 Million	252,981 New	252,981 $12.1 Million
Q3 2018 Oct 15, 2018	SELL	$55.19 - $62.25 $3.21 Million - $3.62 Million	-58,200 Closed	0 $0
Q2 2018 Jul 20, 2018	BUY	$50.53 - $62.98 $2.94 Million - $3.67 Million	58,200 New	58,200 $3.22 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.